Participation and Baseline Characteristics
CWP, ABPA
ABPA, ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS, ASTHMA
Participants were recruited from August 2019 through August 2021, with 2-year follow-up scheduled to finish in August 2023. Sixteen-week follow-up visits continued until December 2021. Of 36 participants screened, one was ineligible (Consolidated Standards of Reporting Trials flow chart.Overall, mean age was 53 years, 63% were female sex, 54% were former smokers, and 43% were never smokers (Baseline CharacteristicsData are presented as No. (%), mean (95% CI) if parametric, or median (interquartile range) if nonparametric (the latter denoted by ∗). 6MWD = 6-min walk distance; ABPA = Allergic Bronchopulmonary Aspergillosis; ACQ6 = Asthma Control Questionnaire 6; AQLQ = Asthma Quality of Life Questionnaire; BD = bronchodilator; BDP = beclomethasone dipropionate; CWP = Counterweight-Plus Programme; DFB = dysfunctional breathing; FIndividuals in the CWP group were slightly older, had lower baseline peak expiratory flow rate and FEV